Key result
Pre-PCI high platelet reactivity linked to ~240% higher risk of periprocedural myonecrosis.
Why the study?
The impact of platelet reactivity on periprocedural myonecrosis in East Asian patients undergoing PCI for stable ischemic heart disease or non-ST elevation ACS is unclear.
Does high platelet reactivity increase the risk of periprocedural myonecrosis in East Asian patients undergoing PCI?
Population
256 East Asian patients with stable ischemic heart disease or non-ST elevation ACS undergoing PCI
Comparison
High platelet reactivity (PRU >208, >235, >272) vs lower platelet reactivity before and after PCI
Design
Cohort study
Follow-up
18-24 hours following PCI
Authors
Loading...
May flag higher PMN risk in East Asians; hypothesis-generating and should not yet change practice.
Cohort (n=256)
Does high platelet reactivity increase the risk of periprocedural myonecrosis in East Asian patients undergoing PCI?
Odds Ratio: 3.39 (95% CI 1.87–6.17)
p-value: p=<.001
Pre-procedural high platelet reactivity is strongly associated with an increased risk of periprocedural myonecrosis in East Asian patients undergoing PCI.
Choi et al. (2019) conducted a cohort in Stable ischemic heart disease or non-ST elevation acute coronary syndrome undergoing PCI (n=256). High platelet reactivity (PRU >208) vs. Optimal platelet reactivity (PRU ≤208) was evaluated on Periprocedural myonecrosis (PMN) (OR 3.39, 95% CI 1.87-6.17, p=<.001). Pre-PCI high platelet reactivity (PRU >208) was associated with an increased risk of periprocedural myonecrosis in patients undergoing PCI (OR 3.39; 95% CI 1.87-6.17; P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: